These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14520124)

  • 1. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly.
    Felix S; Sproule BA; Hardy BG; Naranjo CA
    J Clin Psychopharmacol; 2003 Oct; 23(5):471-8. PubMed ID: 14520124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of high-dosage naproxen in elderly patients.
    Van den Ouweland FA; Jansen PA; Tan Y; Van de Putte LB; Van Ginneken CA; Gribnau FW
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):143-7. PubMed ID: 3410597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the serum protein binding of valproic acid limit the hepatic elimination?
    Kodama Y; Kuranari M; Teraoka I; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):529-32. PubMed ID: 8294164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
    Fattore C; Messina S; Battino D; Croci D; Mamoli D; Perucca E
    Epilepsy Res; 2006 Aug; 70(2-3):153-60. PubMed ID: 16730950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data.
    Battino D; Croci D; Mamoli D; Messina S; Perucca E
    Epilepsy Res; 2004; 59(2-3):155-65. PubMed ID: 15246117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse.
    Löscher W
    J Pharmacol Exp Ther; 1978 Feb; 204(2):255-61. PubMed ID: 340640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data.
    Sriboonruang T; Panomvana D; Chamchitchun S; Silpakit O
    J Clin Psychopharmacol; 2011 Feb; 31(1):115-9. PubMed ID: 21192154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
    Dutta S; Faught E; Limdi NA
    J Clin Pharm Ther; 2007 Aug; 32(4):365-71. PubMed ID: 17635338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
    O'Leary TD; Sansom LN
    J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in clearance of sodium valproate with changes in dose.
    Kilpatrick CJ; Bury RW; Fullinfaw RO; Moulds RF
    Clin Exp Neurol; 1987; 24():97-103. PubMed ID: 3151881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent distribution volumes of total and unbound valproate in guinea-pigs: consequence of non-linear plasma protein binding.
    Yu HY; Shen YZ
    Biopharm Drug Dispos; 1996 Apr; 17(3):237-47. PubMed ID: 8983398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding.
    Aguirre C; Trocóniz IF; Valdivieso A; Jiménez RM; González JP; Calvo R; Rodríguez-Sasiaín JM
    Res Commun Mol Pathol Pharmacol; 1996 Apr; 92(1):53-72. PubMed ID: 8733828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
    Wemer J; Cheng YF; Nilsson D; Reinholdsson I; Fransson B; Lanbeck Vallén K; Nyman L; Eriksson C; Björck S; Schulman S
    Curr Med Res Opin; 2006 Sep; 22(9):1813-23. PubMed ID: 16968585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.
    Ueshima S; Aiba T; Ishikawa N; Sato T; Kawasaki H; Kurosaki Y; Ohtsuka Y; Sendo T
    J Clin Pharm Ther; 2009 Aug; 34(4):415-22. PubMed ID: 19583674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of KW-4679 in the elderly: single-dose and multiple-dose trials.
    Tateishi T; Kobayashi S; Shigeyama C; Nakamura T; Kobayashi H
    Drugs Exp Clin Res; 1998; 24(1):1-7. PubMed ID: 9604143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.